Literature DB >> 22049408

Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A).

Laura Restani1, Flavia Antonucci, Laura Gianfranceschi, Chiara Rossi, Ornella Rossetto, Matteo Caleo.   

Abstract

Botulinum neurotoxin type A (BoNT/A) is a metalloprotease that blocks synaptic transmission via the cleavage of SNAP-25 (synaptosomal-associated protein of 25 kDa). BoNT/A is successfully used in clinical neurology for the treatment of several neuromuscular pathologies and pain syndromes. Despite its widespread use, relatively little is known on BoNT/A intracellular trafficking in neurons. Using the visual pathway as a model system, here we show that catalytically active BoNT/A is capable of undergoing anterograde axonal transport and transcytosis. Following BoNT/A injection into the rat eye, significant levels of BoNT/A-cleaved SNAP-25 appeared in the retinorecipient layers of the superior colliculus (SC). Anterograde propagation of BoNT/A effects required axonal transport, ruling out a systemic spread of the toxin. Cleaved SNAP-25 was present in presynaptic structures of the tectum, but retinal terminals were devoid of the immunoreactivity, indicative of transcytosis. Experiments based on sequential administration of BoNT/A and BoNT/E showed a persistent catalytic activity of BoNT/A in tectal cells following its injection into the retina. Our findings demonstrate that catalytically active BoNT/A is anterogradely transported from the eye to the SC and transcytosed to tectal synapses. These data are important for a more complete understanding of the mechanisms of action of BoNT/A.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22049408      PMCID: PMC6623022          DOI: 10.1523/JNEUROSCI.2618-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

1.  Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt.

Authors:  Shafaq Sikandar; Ynette Gustavsson; Marc J Marino; Anthony H Dickenson; Tony L Yaksh; Linda S Sorkin; Roshni Ramachandran
Journal:  Eur J Neurosci       Date:  2016-05-19       Impact factor: 3.386

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.

Authors:  Abby R Kroken; Faith C Blum; Madison Zuverink; Joseph T Barbieri
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

Review 4.  Mechanism of action of botulinum neurotoxin: Unexpected consequences.

Authors:  Mark Hallett
Journal:  Toxicon       Date:  2017-08-11       Impact factor: 3.033

5.  Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons.

Authors:  Ewa Bomba-Warczak; Jason D Vevea; Joel M Brittain; Annette Figueroa-Bernier; William H Tepp; Eric A Johnson; Felix L Yeh; Edwin R Chapman
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

6.  Multiple domains of tetanus toxin direct entry into primary neurons.

Authors:  Faith C Blum; William H Tepp; Eric A Johnson; Joseph T Barbieri
Journal:  Traffic       Date:  2014-08-11       Impact factor: 6.215

7.  Association of antinociceptive action of botulinum toxin type A with GABA-A receptor.

Authors:  V Drinovac; L Bach-Rojecky; Z Lacković
Journal:  J Neural Transm (Vienna)       Date:  2014-01-14       Impact factor: 3.575

Review 8.  Botulinum toxin type A in motor nervous system: unexplained observations and new challenges.

Authors:  I Matak; Z Lacković; M Relja
Journal:  J Neural Transm (Vienna)       Date:  2016-09-01       Impact factor: 3.575

Review 9.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.